Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.

[1]  I. Thompson,et al.  Pathologic Characteristics of Cancers Detected in the Prostate Cancer Prevention Trial: Implications for Prostate Cancer Detection and Chemoprevention , 2008, Cancer Prevention Research.

[2]  I. Thompson,et al.  Finasteride Does Not Increase the Risk of High-Grade Prostate Cancer: A Bias-Adjusted Modeling Approach , 2008, Cancer Prevention Research.

[3]  T. Wilt,et al.  Five-alpha-reductase Inhibitors for prostate cancer prevention. , 2008, The Cochrane database of systematic reviews.

[4]  P. Gann,et al.  Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. , 2007, Journal of the National Cancer Institute.

[5]  M. Kattan,et al.  Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. , 2007, Journal of the National Cancer Institute.

[6]  I. Thompson,et al.  Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. , 2007, Journal of Clinical Oncology.

[7]  I. Thompson,et al.  Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. , 2007, Journal of the National Cancer Institute.

[8]  A. D'Amico,et al.  Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. , 2007, The Lancet. Oncology.

[9]  Javier Hernandez,et al.  External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. , 2006, Urology.

[10]  I. Thompson,et al.  Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. , 2006, Journal of the National Cancer Institute.

[11]  C. Roehrborn,et al.  The Cost of Prostate Cancer Chemoprevention: A Decision Analysis Model , 2006, Cancer Epidemiology Biomarkers & Prevention.

[12]  Norman Wolmark,et al.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.

[13]  D. Alberts,et al.  The role of prevention in oncology practice: results from a 2004 survey of American Society of Clinical Oncology members. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Ziding Feng,et al.  Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. , 2006, Journal of the National Cancer Institute.

[15]  J. Hafron,et al.  Can self-administered questionnaires supplant objective testing of erectile function? A comparison between the international index of erectile function and objective studies , 2006, International Journal of Impotence Research.

[16]  C. Roehrborn,et al.  Combination Therapy With Doxazosin and Finasteride for Benign Prostatic Hyperplasia in Patients With Lower Urinary Tract Symptoms and a Baseline Total Prostate Volume of 25 Ml or Greater , 2006 .

[17]  L. Ford,et al.  Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. , 2005, Journal of the National Cancer Institute.

[18]  J. Talcott.  Rebalancing ratios and improving impressions: later thoughts from the prostate cancer prevention trial investigators. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  I. Thompson,et al.  Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Ruth Etzioni,et al.  Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. , 2005, The American journal of medicine.

[21]  C. Abdo,et al.  Psychogenic Erectile Dysfunction: Comparative Study of Three Therapeutic Approaches , 2005, Journal of sex & marital therapy.

[22]  D. Penson,et al.  The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study. , 2005, The Journal of urology.

[23]  T. Lue.  Impotence: A patient's goal-directed approach to treatment , 1990, World Journal of Urology.

[24]  B. Kramer,et al.  Cancer prevention and the American Society of Clinical Oncology. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Tindall,et al.  Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. , 2004, The Journal of urology.

[26]  G. Andriole,et al.  Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. , 2004, Urology.

[27]  G. Cunningham,et al.  Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. , 2004, The Journal of clinical endocrinology and metabolism.

[28]  H. Gilbert Welch,et al.  Should I Be Tested for Cancer?: Maybe Not and Here's Why , 2004 .

[29]  C. Roehrborn,et al.  The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. , 2003, The New England journal of medicine.

[30]  P. Rigatti,et al.  A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia , 2003, Prostate Cancer and Prostatic Diseases.

[31]  P. Boyle,et al.  Improvements in benign prostatic hyperplasia‐specific quality of life with dutasteride, the novel dual 5α‐reductase inhibitor , 2003, BJU international.

[32]  Michael M Lieber,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[33]  A. Zuger.  A big study yields big questions. , 2003, The New England journal of medicine.

[34]  G. Andriole,et al.  Safety and Tolerability of the Dual 5α-Reductase Inhibitor Dutasteride in the Treatment of Benign Prostatic Hyperplasia , 2003 .

[35]  M. Kutner,et al.  Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. , 2003, The Journal of urology.

[36]  J. Waldstreicher,et al.  Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. , 2003, Urology.

[37]  P. Boyle,et al.  Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. , 2003, Urology.

[38]  E. Moreira,et al.  Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction. , 2003, Urology.

[39]  E. Lee.  Comparison of Tamsulosin and Finasteride for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia in Korean Patients , 2002, The Journal of international medical research.

[40]  P. Boyle,et al.  Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. , 2002, Urology.

[41]  J. Cappelleri,et al.  The International Index of Erectile Function (IIEF): a state-of-the-science review , 2002, International Journal of Impotence Research.

[42]  S. Kaplan,et al.  Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group. , 2000, Urology.

[43]  I. Osterloh,et al.  Relationship between patient self-assessment of erectile function and the erectile function domain of the international index of erectile function. , 2000, Urology.

[44]  D. Ralph,et al.  UK management guidelines for erectile dysfunction , 2000, BMJ : British Medical Journal.

[45]  D. Summerton,et al.  A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. , 2000, The Journal of urology.

[46]  J. Cappelleri,et al.  Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction , 1999, International Journal of Impotence Research.

[47]  G. Broderick,et al.  Sex inventories: can questionnaires replace erectile dysfunction testing? , 1999, Urology.

[48]  I. Osterloh,et al.  Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. , 1999, Urology.

[49]  I. Osterloh,et al.  Some Developments on the International Index of Erectile Function (IIEF) , 1999 .

[50]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[51]  S. Kaplan,et al.  Increased incidence of depressive symptoms in men with erectile dysfunction. , 1998, Urology.

[52]  E. Crawford,et al.  Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. , 1998, Urology.

[53]  M. Pike,et al.  The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels. , 1998, British Journal of Cancer.

[54]  A. Araujo,et al.  The Relationship Between Depressive Symptoms and Male Erectile Dysfunction: Cross-Sectional Results From the Massachusetts Male Aging Study , 1998, Psychosomatic medicine.

[55]  C. Roehrborn,et al.  The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia , 1998 .

[56]  M. Elhilali,et al.  Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. , 1996, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[57]  H. Lepor,et al.  The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. , 1996, The New England journal of medicine.

[58]  A. Melman,et al.  Accuracy of the initial history and physical examination to establish the etiology of erectile dysfunction. , 1995, Urology.

[59]  E. Round,et al.  CLINICAL-EXPERIENCE OF THE DETECTION OF PROSTATE-CANCER IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA TREATED WITH FINASTERIDE , 1994 .

[60]  E. Stoner,et al.  Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. , 1994, Urology.

[61]  E. Stoner.  Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group. , 1994, Archives of internal medicine.

[62]  G. Andriole,et al.  The effect of finasteride in men with benign prostatic hyperplasia. , 1992, The Journal of urology.

[63]  R. Chlebowski,et al.  Current attitudes and practice of American Society of Clinical Oncology-member clinical oncologists regarding cancer prevention and control. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.